PDS Biotechnology (PDSB) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rafael (RFL) has outperformed PDS Biotechnology (PDSB) over the past year, gaining 9.6% versus a gain of 2.0%. Over five years, PDSB leads with a -91.7% price change compared with -95.1% for RFL. Rafael is the larger company by market cap ($77.0 million vs $73.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PDSB | RFL |
|---|---|---|
| Share price | $1.02 | $1.48 |
| Market cap | $73.92M | $76.96M |
| 1-day change | -4.23% | 0.00% |
| YTD return | +32.47% | +25.42% |
| 1-year return | +2.00% | +9.63% |
| 5-year return | -91.73% | -95.09% |
| EPS (TTM) | $-0.64 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.55 | $3.96 |
| 52-week low | $0.195 | $1.12 |
| Distance from 52-week high | -34.19% | -62.63% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +390.20% | — |
| Average volume | 23.24M | 159.84K |
| Shares outstanding | 72.47M | 51.21M |
| Employees | 21 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
PDSB vs RFL FAQ
Which is bigger, PDS Biotechnology or Rafael?
Rafael (RFL) is larger, with a market capitalization of $76.96M compared with $73.92M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, PDSB or RFL?
RFL returned +9.63% over the past 12 months, compared with +2.00% for PDSB (price return, excluding dividends). Past performance does not predict future results.
Are PDS Biotechnology and Rafael in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.